{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:05:13Z","timestamp":1778493913938,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T00:00:00Z","timestamp":1414454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Protalix BioTherapeutics"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bcmd.2014.10.002","type":"journal-article","created":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T17:43:26Z","timestamp":1415382206000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease"],"prefix":"10.1016","volume":"54","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derlis Emilio","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Abrahamov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alona","family":"Paz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einat","family":"Brill-Almon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2014.10.002_bb0005","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"1","article-title":"Gaucher disease","author":"Grabowski","year":"2010"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0015","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry","volume":"31","author":"Fairley","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0020","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.21305","article-title":"Life expectancy in Gaucher disease type 1","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","article-title":"The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis","volume":"160","author":"Kaplan","year":"2006","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpeds.2003.10.067","article-title":"Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations","volume":"144","author":"Charrow","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","article-title":"Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements","volume":"163","author":"Grabowski","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0045","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nbt0612-472","article-title":"First plant-made biologic approved","volume":"30","author":"Fox","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd3369","article-title":"\u2018Pharmers\u2019 hope for first plant drug harvest","volume":"10","author":"Opar","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nm0112-5","article-title":"Drugmaker reaps what it sows with first plant-made biologic","volume":"18","author":"Williams","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0065","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1371\/journal.pone.0004792","article-title":"A plant-derived recombinant human glucocerebrosidase enzyme\u2014a preclinical and phase I investigation","volume":"4","author":"Aviezer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0070","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2010.10.009","article-title":"Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model","volume":"46","author":"Bracoud","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0080","author":"World Health Organization"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0085","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(95)91688-1","article-title":"Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype","volume":"346","author":"Abrahamov","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1034\/j.1399-0004.2001.590511.x","article-title":"Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation","volume":"59","author":"George","year":"2001","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0095","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.bcmd.2014.10.002_bb0100","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ymgme.2009.10.173","article-title":"Enzyme replacement therapy with velaglucerase alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease [abstract 156]","volume":"90","author":"Zimran","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0110","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","article-title":"Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"27","author":"Khan","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0115","first-page":"158","article-title":"Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy","volume":"2","author":"Kauli","year":"2000","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2014.10.002_bb0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Quality of life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual. Life Res."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614001193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614001193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:37Z","timestamp":1761049837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979614001193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1079979614001193"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.10.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}